Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of dasatinib maintenance after allogeneic hematopoietic stem cell transplantation in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia
2009-015118-23Phase 2Completed
- Sponsor
- GETH-TC
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by GETH-TC. Primary endpoint: Disease-free survival at 2 years. Started Oct 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-015118-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015118-23.